Current Illinois CancerCare Clinical Trals

Pancreatic


A022106 (JIT)

Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)


EA2192

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation


EAY191 – A3

Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial


EAY191 – E4 (Suspended)

Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors: A ComboMATCH Treatment Trial (Suspended)


RAIN-3202 (JIT)

A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors


S2001

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations


S2104 (JIT)

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors


Search Again